InfuSystem (INFU) & Its Competitors Financial Analysis

InfuSystem (NYSE:INFU) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its rivals? We will compare InfuSystem to related companies based on the strength of its institutional ownership, profitability, analyst recommendations, earnings, valuation, dividends and risk.

Insider and Institutional Ownership

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares InfuSystem and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InfuSystem	$144.44 million	$870,000.00	33.01
InfuSystem Competitors	$19.21 billion	$301.67 million	7.03

InfuSystem’s rivals have higher revenue and earnings than InfuSystem. InfuSystem is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, InfuSystem’s rivals have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares InfuSystem and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
InfuSystem Competitors	-8.06%	-136.93%	-1.64%

Analyst Ratings

This is a summary of recent recommendations for InfuSystem and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0	0	2	0	3.00
InfuSystem Competitors	1871	7744	13372	828	2.55

InfuSystem currently has a consensus price target of $17.50, indicating a potential upside of 17.81%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.25%. Given InfuSystem’s stronger consensus rating and higher probable upside, equities analysts clearly believe InfuSystem is more favorable than its rivals.

Summary

InfuSystem beats its rivals on 9 of the 13 factors compared.

About InfuSystem

InfuSystem Holdings, Inc. provides infusion pumps, related medical equipment and support services to healthcare providers and patients. Its products are used in settings such as hospitals, clinics and patients’ homes, including for oncology and pain-management therapies. The company operates through its Integrated Therapy Services and Durable Medical Equipment Services businesses. Its offerings include infusion pump rentals and sales, equipment management, biomedical services, clinical support and related supplies.